

## **FISCAL NOTE**

January 6, 2020

| Bill No: HB 410 | Printer's No: | 385 | Sponsor: | Oberlander (R) |
|-----------------|---------------|-----|----------|----------------|
|-----------------|---------------|-----|----------|----------------|

## COST / (SAVINGS)

| Fund (s)     | 2019-20        | 2020-21        |
|--------------|----------------|----------------|
| General Fund | \$88.6 million | \$88.6 million |

**SUMMARY:** This bill adds anti-obesity drugs to the Medical Assistance program.

**ANALYSIS:** HB 410 establishes anti-obesity drugs approved by the federal government shall be considered a compensable item under the Medical Assistance (MA) program.

**FISCAL IMPACT:** Adding anti-obesity drugs as a compensable item under MA would carry an estimated annual cost of \$88.6 million.

| Total MA    | Obesity rate | Potential MA | Estimated        | Cost per | Annual Cost    |
|-------------|--------------|--------------|------------------|----------|----------------|
| population  |              | participants | utilization rate | patient  |                |
| 1.9 million | 31.6 percent | 600,449      | 10 percent       | \$1,500  | \$88.6 million |

Assuming an obesity rate of 31.6 percent in the total MA population of 1.9 million individuals, 600,449 would potentially seek anti-obesity drugs. At an estimated utilization rate of 10 percent and cost per patient of \$1,500, the annual cost to MA totals \$88.6 million.